Biao Li

Biao Li is a highly experienced bioinformatics professional currently serving as Principal Scientist at Revolution Medicines, focusing on innovative cancer therapies. Prior to this role, Biao held significant positions at Seer as Staff Data Scientist, where contributions included analytics leadership for the launch of Proteograph XT, the development of a cloud-based analytics platform, and the creation of a CNN model for real-time quality control. Biao's earlier experience at Illumina encompassed various roles in bioinformatics, including Senior Bioinformatics Scientist, contributing to non-invasive prenatal testing (NIPT) products and assay performance improvements. Academic credentials include a Ph.D. in Bioengineering from Rice University and a Bachelor's in Bioengineering from Beihang University, complemented by research at Baylor College of Medicine and MD Anderson Cancer Center.